skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Global Search Configuration

Understand the latest Corporate Strategies of the biggest Generics and Biosimilar players.

Get an inside view into the corporate strategies of generics’ biggest players with articles like: 
  • Teva Takes A Further Hit On Value Of Actavis
  • Slowing Biopharmaceuticals Puts A Dent In Sandoz’ Sales
  • Wait For Strategic Decisions Weighs Heavily On Mylan
  • If Amneal Goes Global Again, It Intends To Go Big
Corporate Strategies of the biggest Generics and Biosimilar players

Read also

  • Generics Bulletin

    Finalists revealed for CPhI Worldwides eagerly anticipated 2019 Awards

    London, 17 October 2019: CPhI Worldwide announces the finalists for the CPhI Pharma Awards. The shortlist spans 13 different categories across the full spectrum of the pharmaceutical supply chain, including Formulation, Packaging and Lifetime Achievement Awards.

  • Scrip: industry news and insights, Pink Sheet: global policy...

    Mega Mergers

    When it comes to M&A, Informa Pharma Insights has got it covered. Our readers benefit from exclusive executive interviews with industry leaders and expert analysts on business, pipeline and M&A strategy, broad and detailed coverage on implications of deal-making from antitrust to quality compliance, commercial and R&D infrastructure, regional repercussions and the impact on existing partners. 2019 has already been notable for major deals, from the closing of the $62bn Takeda/Shire acquisition to the agreed purchases of Celgene for $74bn by Bristol-Myers Squibb and of Allergan for $63bn by AbbVie, to Pfizer’s plan to merge its Upjohn generics business with Mylan.

    Topics Business strategies

  • Generics Bulletin

    Executive and market moves interviews for exclusive insider knowledge

    Get in the side track on the Generics market with executive and market-moves interviews for exclusive insider knowledge. 

    Topics Business strategies


Next steps

Whether you’re a small biotech start-up, research firm, generic manufacturer or a global pharmaceutical giant, you need focused, independent insight and opinion on market developments.

Our team is always happy to hear from you. Please call us at:

  • US Toll-Free  : +1 888 670 8900
  • US Toll           : +1 908 547 2200
  • UK & Europe : +44 (20) 337 73737
  • Australia        : +61 2 8705 6907
  • Japan              : +81 3 6273 4260

Or please submit your inquiry via the form so that we can provide you the best possible customer service.

Have an immediate and specific information need?

Browse and buy from 1000s of analysis and research reports now: